Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 ICRF 159, (+/-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane.

× No keyword cloud information.

13 in total

1. Combined razoxane and radiotherapy for melanoma brain metastases. a retrospective analysis.

Authors: Walter Rhomberg; Helmut Eiter; Franz Boehler; Christoph Saely; Robert Strohal
Journal: J Neurooncol Date: 2005-09 Impact factor: 4.130

Review 2. New cancer chemotherapy drugs in Europe.

Authors: G Mathé; L M van Putten
Journal: Cancer Chemother Pharmacol Date: 1978 Impact factor: 3.333

3. Anticancer chemotherapy.

Authors: P Davey; G R Tudhope
Journal: Br Med J (Clin Res Ed) Date: 1983-07-09

4. Adjuvant oral razoxane (ICRF-159) in resectable colorectal cancer.

Authors: J M Gilbert; K Hellmann; M Evans; P G Cassell; B Stoodley; H Ellis; C Wastell
Journal: Cancer Chemother Pharmacol Date: 1982 Impact factor: 3.333

5. The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).

Authors: B B Hasinoff
Journal: Agents Actions Date: 1990-03

6. The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin.

Authors: B B Hasinoff
Journal: Agents Actions Date: 1989-03

7. The cytokinetic and cytotoxic effects of ICRF-159 and ICRF-187 in vitro and ICRF-187 in human bone marrow in vivo.

Authors: R H Wheeler; D J Clauw; R B Natale; R W Ruddon
Journal: Invest New Drugs Date: 1983 Impact factor: 3.850

8. Lead elimination of ICRF 158 in rats after chronic lead exposure.

Authors: U Witting; E Hultsch
Journal: Int Arch Occup Environ Health Date: 1981 Impact factor: 3.015

9. Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192.

Authors: Z X Huang; P M May; K M Quinlan; D R Williams; A M Creighton
Journal: Agents Actions Date: 1982-10

10. Prospective serial liver ultrasound scanning in resectable colorectal cancer treated with adjuvant razoxane.

Authors: R H Taylor; J M Gilbert; M G Evans; H G Lane; P G Cassell
Journal: Clin Exp Metastasis Date: 1984 Oct-Dec Impact factor: 5.150